Stage (next event)
Phase 3 Data
Catalyst Info & Data Links
TITLE: Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction (HFrEF) - Phase 3
ClinicalTrials.gov (NCT02929329): Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)
WHAT IS THE NEXT CATALYST EVENT?
Phase 3 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2020: Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure
Mechanism of Action
MECHANISM OF ACTION
Omecamtiv mecarbil stimulates cardiac myosin, a protein responsible for converting chemical energy into the mechanical force that results in contraction of the heart. It is designed to improve cardiac muscle performance, potentially helping patients preserve cardiac function and quality of life, avoid hospitalizations, and decrease the risk of death due to heart failure. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post